63240-26-6

Basic information

• Product Name: 2-Bromo-4-nitro-naphthalen-1-ylamine
• Synonyms: 2-Bromo-4-nitro-naphthalen-1-ylamine;2-bromo-4-nitronaphthalen-1-amine HBr
• CAS NO: 63240-26-6
• Molecular Formula: C10H7BrN2O2
• Molecular Weight: 267.07878
• Mol File: 63240-26-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 250 °C
• Boiling Point: 436.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.735±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -1.84±0.10(Predicted)
• CAS DataBase Reference: 2-Bromo-4-nitro-naphthalen-1-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-4-nitro-naphthalen-1-ylamine(63240-26-6)
• EPA Substance Registry System: 2-Bromo-4-nitro-naphthalen-1-ylamine(63240-26-6)

Safety Data

• Hazardous Substances Data: 63240-26-6(Hazardous Substances Data)

Upstream product

• 575-36-0 1-acetamidonaphthalene 
• 776-34-1 1-amino-4-nitronaphthalene 
• 64-19-7 acetic acid 
• 98-95-3 nitrobenzene 

Downstream Products

• 90766-34-0 3-bromonaphthalen-1-amine 
• 90767-17-2 3-bromo-1-hydroxynaphthalene 
• 102153-47-9 3-bromo-1-nitronaphthalene 

Relevant articles and documents

-

-

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

Development of new cathepsin b inhibitors: Combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives

Human cathepsin B has many house-keeping functions, such as protein turnover in lysosomes. However, dysregulation of its activity is associated with numerous diseases, including cancers. We present here the structure-based design and synthesis of new cathepsin B inhibitors using the cocrystal structure of 5-nitro-8-hydroxyquinoline in the cathepsin B active site. A focused library of over 50 compounds was prepared by modifying positions 5, 7, and 8 of the parent compound nitroxoline. The kinetic parameters and modes of inhibition were characterized, and the selectivities of the most promising inhibitors were determined. The best performing inhibitor 17 was effective in cell-based in vitro models of tumor invasion, where it significantly abrogated invasion of MCF-10A neoT cells. These data show that we have successfully explored the structure-activity relationships of nitroxoline derivatives to provide new inhibitors that could eventually lead to compounds with clinical usefulness against the deleterious effects of cathepsin B in cancer progression.